Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis.

Masahiro Toda Yoshiharu Yamanobe Masato FujiokaYukina MorimotoMariko FukumuraMasato NakayaYumiko OishiMizuto SatoRyo UedaHirokazu FujiwaraTetsuro HikichiShinobu Noji Naoki OishiHiroyuki OzawaKaoru OgawaYutaka KawakamiTakayuki OhiraKazunari YoshidaMasahiro Toda

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

This study demonstrated the safety and preliminary efficacy of VEGFR peptide vaccination in patients with NF2. Memory-induced CTLs after VEGFR vaccination may persistently suppress tumor progression.

Keyphrases

vascular endothelial growth factor
signaling pathway
endothelial cells
lps induced
high glucose
poor prognosis
pi k akt
nuclear factor
cell proliferation
inflammatory response
immune response
stress induced